Biomarkers in the diagnosis of lysosomal storage disorders: Proteins, lipids, and inhibodies

Journal of Inherited Metabolic Disease

Volumn 34, Issue 3, 2011, Pages 605-619

  Aerts, Johannes M F G ^a   Kallemeijn, Wouter W ^a   Wegdam, Wouter ^a   Joao Ferraz, Maria ^a   Van Breemen, Marielle J ^a   Dekker, Nick ^a   Kramer, Gertjan ^a   Poorthuis, Ben J ^a   Groener, Johanna E M ^a   Cox Brinkman, Josanne ^a   Rombach, Saskia M ^a   Hollak, Carla E M ^a   Linthorst, Gabor E ^a   Witte, Martin D ^b   Gold, Henrik ^b   Van Der Marel, Gijs A ^b   Overkleeft, Herman S ^b   Boot, Rolf G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA GALACTOSIDASE; C REACTIVE PROTEIN; CCL18 CHEMOKINE; CHEMOKINE; CHITOTRIOSIDASE; GANGLIOSIDE GM3; GELATINASE B; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; GLUCOSYLCERAMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYELOPEROXIDASE; PHOSPHATIDYLGLYCEROL; SPHINGOLIPID; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE MARKER; FABRY DISEASE; GAUCHER DISEASE; GENE MUTATION; HUMAN; IMMUNOASSAY; INCIDENCE; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; LYSOSOME STORAGE DISEASE; MASS SPECTROMETRY; NONHUMAN; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPTOM;

ANIMALS; ANTIBODIES; BIOLOGICAL MARKERS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GAUCHER DISEASE; HUMANS; LIPIDS; LYSOSOMAL STORAGE DISEASES; MODELS, MOLECULAR; PROTEINS;

EID: 79959803398     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9308-6     Document Type: Conference Paper

References (162)

1. Aerts JM, Hollak CE (1997) Plasma and metabolic abnormalities in Gaucher's disease. Baillières Clin Haematol 10:691-709 (Pubitemid 28022203)
2. Aerts JM, Donker-Koopman WE, van der Vliet MK, Jonsson LM, Ginns EI, Murray GJ, Barranger JA, Tager JM, Schram AW (1985) The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen. Eur J Biochem 150(3):565-574 (Pubitemid 15024833)
3. Aerts JM, Donker-Koopman WE, Murray GJ, Barranger JA, Tager JM, Schram AW (1986a) A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies. Anal Biochem 154:655-663 (Pubitemid 16075308)
4. Aerts JM, Donker-Koopman WE, Koot M, Barranger JA, Tager JM, Schram AW (1986b) Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta 158:155-163
5. Aerts JM, Schram AW, Strijland A, vanWeely S, Jonsson LM, Tager JM, Sorrell SH, Ginns EI, Barranger JA, Murray GJ (1988) Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. Biochim Biophys Acta 964:303-308 (Pubitemid 18084980)
6. Aerts JM, Van Weely S, Boot R, Hollak CE, Tager JM (1993) Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease. J Inherit Metab Dis 16:288-291 (Pubitemid 23213651)
7. Aerts JM, Hollak C, Boot R, Groener A (2003) Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 358:905-914 (Pubitemid 36639715)
8. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M (2006) Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 29:449-456 (Pubitemid 43880650)
9. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS (2007) Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56:1341-1349 (Pubitemid 46715620)
10. Aerts JM, van Breemen MJ, Bussink AP, Ghauharali K, Sprenger R, Boot RG, Groener JE, Hollak CE, Maas M, Smit S, Hoefsloot HC, Smilde AK, Vissers JP, de Jong S, Speijer D, de Koster CG (2008a) Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr Suppl 97:7-14 (Pubitemid 351421284)
11. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008b) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812-2817 (Pubitemid 351723626)
12. Aerts JM, Yasothan U, Kirkpatrick P (2010) Velaglucerase alfa. Nat Rev Drug Discov 9:837-838
13. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, Out JM, Donker-Koopman WE, Groener JE, Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273:25680-25685
14. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, Out JM, Donker-Koopman WE, Groener JE, Boot RG, Renkema GH, van der Marel GA, van Boom JH, Overkleeft HS, Aerts JM et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278:40911-40916 (Pubitemid 37280911)
15. Atsumi S, Nosaka C, Iinuma H, Umezawa K (1993) Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. Arch Biochem Biophys 304:302-304 (Pubitemid 23214185)
16. Auray-Blais C, Cyr D, Mills K, Giguère R, Drouin R (2007) Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J Inherit Metab Dis 30:106
17. Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JT, Drouin R (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 93:331-340 (Pubitemid 351192345)
18. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R (2010) How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 411:1906-1914
19. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E (2009) A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS ONE 4:e4792
20. Balreira A, Gaspar P, Caiola D, Chaves J, Beirão I, Lima JL, Azevedo JE, Miranda MC (2008) A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum Mol Genet 17:2238-2243 (Pubitemid 351911989)
21. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, Steinmann B, Burnier M, Palecek T, Bultas J, Hayoz D (2006a) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26:839-844 (Pubitemid 43732160)
22. Barbey F, Brakch N, Linhart A, Jeanrenaud X, Palecek T, Bultas J, Burnier M, Hayoz D (2006b) Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl 95:63-68 (Pubitemid 43739098)
23. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464-1470
24. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29-45
25. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F (2006) The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 4(4):289-297 (Pubitemid 44574840)
26. Beutler E, Grabowski G (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York, pp 3635-3668
27. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE (2008) 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 31:337-349
28. Biegstraaten M, van Schaik IN, Aerts JM, Langeveld M, Mannens MM, Bour LJ, Sidransky E, Tayebi N, Fitzgibbon E, Hollak CE (2010) A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cells Mol Dis 46:39-41
29. Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM (1996) Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 237:344-349
30. Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JM (2003) Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet 72:23-31 (Pubitemid 36056840)
31. Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C (2010) Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 57:123-145
32. Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE (2010) Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol Dis 44:181-739
33. Boot RG, Renkema GH, Strijland A, Van Zonneveld AJ, Aerts JM (1995) Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 270:26252-26256
34. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 19:687-694 (Pubitemid 29135172)
35. Boot RG, Blommaart EF, Swart E, Ghauharali-van der Vlugt K, Bijl N, Moe C, Place A, Aerts JM (2001) Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 276:6770-6778
36. Boot RG, Verhoek M, De Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33-39 (Pubitemid 38029915)
37. Boot RG, Verhoek M, Langeveld M, Renkema GH, Hollak CE, Weening JJ, Donker-Koopman WE, Groener JE, Aerts JM (2006) CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis 29:564-571 (Pubitemid 44193272)
38. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JM (2007) Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem 282:1305-1312
39. Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM (2010) Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta 411:31-36
40. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP (2002) Arterial remodelling in Fabry disease. Acta Paediatr Suppl 91:62-66 (Pubitemid 36174153)
41. Boven LA, Van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359-369 (Pubitemid 39145540)
42. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD (2006) Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129:517-526 (Pubitemid 43164373)
43. Brady RO, Kanfer JN, Bradley RM, Shapiro D (1966) Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 45:1112-1115
44. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163-1167
45. Brinkman J, Wijburg FA, Hollak CE, Groener JE, Verhoek M, Scheij S, Aten J, Boot RG, Aerts JM (2005) Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann- Pick disease. J Inherit Metab Dis 28:13-20 (Pubitemid 40253980)
46. Bussink AP, Van Eijk M, Renkema GH, Aerts JM, Boot RG (2006) The biology of the Gaucher cell: the cradle of human chitinases. Int Rev Cytol 252:71-128 (Pubitemid 44375087)
47. Bussink AP, Speijer D, Aerts JM, Boot RG (2007) Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 177:959-970 (Pubitemid 350005647)
48. Bussink AP, Verhoek M, Vreede J, Ghauharali-van der Vlugt K, Donker-Koopman WE, Sprenger RR, Hollak CE, Aerts JM, Boot RG (2009) Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. FEBS J 276:5678-5688
49. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481-1485 (Pubitemid 30237353)
50. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A (2003) Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513-526
51. Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N (2008) Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 31:319-336
52. Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CE, Wijburg FA, Aerts JM (2008) Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis 31:745-752
53. de Duve C, Pressman B, Gianetto R, Wattieux R, Pelsmans F (1955) Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 60:604-617
54. de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Wiersma MG, Häussinger D, Brett S, Brill N, vom Dahl S (2007) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108:830-835 (Pubitemid 44154614)
55. de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG, Aerts JF, Maas M, Vom Dahl S, Hollak CE (2008) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87:439-449
56. de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JE, de Groot E, Mannens MM, Bikker H, Aerts JM, Kastelein JJ, Hollak CE (2009) Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204:267-272
57. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, Cox TM (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35:259-267 (Pubitemid 41267058)
58. Dekker N, Voorn-Brouwer T, Verhoek M, Wennekes T, Narayan RS, Speijer D, Hollak CE, Overkleeft HS, Boot RG, Aerts JM (2010) The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation. Blood Cells Mol Dis 46:19-26
59. Desnick RJ, Ioannou YA (2001) α-Galactosidase a deficiency. Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733-3774
60. Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M, Hanson S, Passage M, Kakkis E (2007) Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 91:61-68 (Pubitemid 46550919)
61. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757-766 (Pubitemid 39433603)
62. Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JF, van Weely S, Zimran A (2007) Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 110:2296-2301 (Pubitemid 47523147)
63. EMEA (2006) Report on the EMEA/CHMP Biomarkers Workshop, European Medicines Agency https://cbe0snz9r6ebbswtfa67p.sec.amc.nl/pdfs/human/biomarkers/ 42720905en.pdf
64. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE (2001) International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 345:9-16 (Pubitemid 32634266)
65. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE (2006) Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 95:312-317
66. Fauler G, Rechberger GN, Devrnja D, Erwa W, Plecko B, Kotanko P, Breunig F, Paschke E (2005) Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid Commun Mass Spectrom 19:1499-1506 (Pubitemid 40801992)
67. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307-314 (Pubitemid 37324717)
68. Fuller M, Sharp PC, Rozaklis T, Whitfield PD, Blacklock D, Hopwood JJ, Meikle PJ (2005) Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin Chem 51:688-694 (Pubitemid 40463920)
69. Fusetti F, von Moeller H, Houston D, Rozeboom HJ, Dijkstra BW, Boot RG, Aerts JM, van Aalten DM (2002) Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinase-like lectins. J Biol Chem 277:25537-25544 (Pubitemid 34951869)
70. Ghauharali-van der Vlugt K, Langeveld M, Poppema A et al (2007) Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 389:109-113
71. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65:1353-1357
72. Groener JE, Poorthuis BJ, Kuiper S, Helmond MT, Hollak CE, Aerts JM (2007) HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin Chem 53:742-747 (Pubitemid 46580247)
73. Groener JE, Poorthuis BJ, Kuiper S, Hollak CE, Aerts JM (2008) Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta 1781:72-78
74. Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE, Hollak CE, Aerts JM, Galjaard H, van Diggelen OP (1995) Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 18:717-722 (Pubitemid 26007546)
75. Hein LK, Meikle PJ, Hopwood JJ, Fuller M (2007) Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab 92:336-345 (Pubitemid 350117716)
76. Heitner R, Elstein D, Aerts J, Weely S, Zimran A (2002) Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 28(2):127-133 (Pubitemid 34743745)
77. Hers HG (1963) α-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 86:11-16
78. Hollak CE, Van Weely S, Van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288-1292
79. Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345:1474-1478
80. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH (1997a) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96:470-476 (Pubitemid 27087229)
81. Hollak CE, Evers L, Aerts JM, van Oers MH (1997b) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201-212 (Pubitemid 27469455)
82. Hollak C, Maas M, Aerts J (2001) Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis 24 (Suppl 2):97-105 (Pubitemid 33061639)
83. Iyer A, van Eijk M, Silva E, Hatta M, Faber W, Aerts JM, Das PK (2009) Increased chitotriosidase activity in serum of leprosy patients: association with bacillary leprosy. Clin Immunol 131:501-509
84. Kalliokoski RJ, Kalliokoski KK, Penttinen M, Kantola I, Leino A, Viikari JS, Simell O, Nuutila P, Raitakari OT (2006) Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis 29:660-666 (Pubitemid 44390429)
85. Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 67:2045-2047 (Pubitemid 44967388)
86. Labadaridis J, Dimitriou E, Costalos C, Aerts J, van Weely S, Donker-Koopman WE, Michelakakis H (1998) Serial chitotriosidase activity estimations in neonatal systemic candidiasis. Acta Paediatr 87:605
87. Langeveld M, Scheij S, Dubbelhuis P, Hollak CE, Sauerwein HP, Simons P, Aerts JM (2007) Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. Metabolism 56:314-319 (Pubitemid 46209222)
88. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE (2008b) Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 40:428-432 (Pubitemid 351512343)
89. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, Aerts JM, Serlie MJ (2008a) Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab 93(3):845-851 (Pubitemid 351398562)
90. Langeveld M, Aerts JM (2009) Glycosphingolipids and insulin resistance. Prog Lipid Res 48:196-205
91. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589-1595 (Pubitemid 39298394)
92. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217-222
93. Liou B, Grabowski GA (2009) Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease. Mol Genet Metab 97:65-74
94. Lonser RR, Walbridge S, Murray GJ, Aizenberg MR, Vortmeyer AO, Aerts JM, Brady RO, Oldfield EH (2005) Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol 57:542-8.31
95. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ (2010a) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116:893-899
96. Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ (2010b) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116:4095-4098
97. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ (2002) Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179:961-965
98. Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience. Radiology 229:554-561 (Pubitemid 37310846)
99. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91:259-267 (Pubitemid 46819125)
100. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249-254 (Pubitemid 29058114)
101. Meikle PJ, Whitfield PD, Rozaklis T, Blacklock D, Duplock S, Elstein D, Zimran A, Mengel E, Cannell P, Hopwood JJ, Fuller M (2008) Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cells Mol Dis 40:420-427 (Pubitemid 351508448)
102. Michelakakis H, Spanou C, Kondyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM (1996) Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1317:219-222 (Pubitemid 26426550)
103. Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, Winchester B (2004) Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr 163:595-603 (Pubitemid 39362536)
104. Møller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK (2004) Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 72:135-139 (Pubitemid 38161162)
105. Moore DF, Kaneski CR, Askari H, Schiffmann R (2007a) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257(1-2):258-263 (Pubitemid 46856501)
106. Moore DF, Krokhin OV, Beavis RC, Ries M, Robinson C, Goldin E, Brady RO, Wilkins JA, Schiffmann R (2007b) Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci USA 104:2873-2878 (Pubitemid 46327972)
107. Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM (2000) Pathologic gene expression in Gaucher disease: upregulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96:1969-1978 (Pubitemid 30662113)
108. Ohashi T, Hong CM, Weiler S, Tomich JM, Aerts JM, Tager JM, Barranger JA (1991) Characterization of human glucocerebrosidase from different mutant alleles. J Biol Chem 266:3661-3667 (Pubitemid 21909263)
109. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94:2540-2544 (Pubitemid 27136911)
110. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymańska A (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Suppl 5):4-14 (Pubitemid 39311677)
111. Phenix CP, Rempel BP, Colobong K, Doudet DJ, Adam MJ, Clarke LA, Withers SG (2010) Imaging of enzyme replacement therapy using PET. Proc Natl Acad Sci USA 107:10842-10847
112. Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, Cox TM, Lachmann RH, Hollak C, Aerts JM, Van Weely S, Hrebícek M, Moyses C, Gow I, Elstein D, Zimran A (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24:275-290 (Pubitemid 32479421)
113. Poll LW, Koch JA, Willers R, Aerts H, Scherer A, Häussinger D, Mödder U, vom Dahl S (2002) Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 28:209-220 (Pubitemid 34743755)
114. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151-156 (Pubitemid 29396979)
115. Popli S, Leehey DJ, Molnar ZV, Nawab ZM, Ing TS (1990) Demonstration of Fabry's disease deposits in placenta. Am J Obstet Gynecol 162:464-465 (Pubitemid 20068521)
116. Rao FV, Houston DR, Boot RG, Aerts JM, Sakuda S, van Aalten DM (2003) Crystal structures of allosamidin derivatives in complex with human macrophage chitinase. J Biol Chem 278:20110-20116 (Pubitemid 36799205)
117. Rao FV, Houston DR, Boot RG, Aerts JM, Hodkinson M, Adams DJ, Shiomi K, Omura S, van Aalten DM (2005) Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. Chem Biol 12:65-76 (Pubitemid 40118327)
118. Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131:770-783 (Pubitemid 350087202)
119. Rempel BP, Withers SG (2008) Covalent inhibitors of glycosidases and their applications in biochemistry and biology. Glycobiology 18:570-586
120. Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM (1995) Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem 270:2198-2202
121. Renkema GH, Boot RG, Strijland A, Donker-Koopman WE, van den Berg M, Muijsers AO, Aerts JM (1997) Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. Eur J Biochem 244:279-285
122. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM (1998) Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 251:504-509 (Pubitemid 28080953)
123. Rijnboutt S, Aerts HM, Geuze HJ, Tager JM, Strous GJ (1991a) Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. J Biol Chem 266:4862-4868 (Pubitemid 21909434)
124. Rijnboutt S, Kal AJ, Geuze HJ, Aerts H, Strous GJ (1991b) Mannose 6-phosphate-independent targeting of cathepsin D to lysosomes in HepG2 cells. J Biol Chem 266:23586-23592 (Pubitemid 21908837)
125. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, van den Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM (2010a) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802:741-748
126. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE (2010b) Vasculopathy in patients with Fabry disease: current controversies and
127. Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A (2010) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant [Epub ahead of print]
128. Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW (1997) Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 42:613-621 (Pubitemid 27439024)
129. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743-2749 (Pubitemid 32525371)
130. Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65-77
131. Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CE, Groener JE, Aerts JM (2007) Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381:136-139 (Pubitemid 46719145)
132. Shah JS, Hughes DA, Tayebjee MH, MacFadyen RJ, Mehta AB, Elliott PM (2007) Extracellular matrix turnover and disease severity in Anderson-Fabry disease. J Inherit Metab Dis 30:88-95 (Pubitemid 46140230)
133. Sidransky E (2004) Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 83:6-15
134. Smid BE, Aerts JM, Boot RG, Linthorst GE, Hollak CE (2010) Pharmacological small molecules for the treatment of lysosomal storage disorders. Expert Opin Investig Drugs 19:1367-1379
135. Tan MA, Dean CJ, Hopwood JJ, Meikle PJ (2008) Diagnosis of metachromatic leukodystrophy by immune quantification of arylsulphatase A protein and activity in dried blood spots. Clin Chem 54:1925-1927
136. Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, Kanekura T, Sakuraba H (2010a) Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem Biophys Res Commun 399:716-720
137. Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H (2010b) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100:257-261
138. Urayama A, Grubb JH, Banks WA, Sly WS (2007) Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor. Proc Natl Acad Sci USA 104:12873-12878
139. van Breemen MJ, Bleijlevens B, de Koster CG, Aerts JM (2006) Limitations in quantitation of the biomarker CCL18 in Gaucher disease blood samples by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry. Biochim Biophys Acta 1764:1626-1632 (Pubitemid 44548542)
140. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772:788-796 (Pubitemid 46891215)
141. van Breemen MJ, Aerts JM, Sprenger RR, Speijer D (2008) Potential artefacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities. Clin Chim Acta 396:26-32
142. van Breemen MJ, de Fost M, Maas M, Wiersma MG, Hollak CE, Poll LW, Vom Dahl S, Boot RG, Aerts JM (2009) Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy. J Inherit Metab Dis 32:274-279
143. van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, Wanner C, Aerts JM, Hollak CE (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812:70-76
144. van Eijk M, van Roomen CP, Renkema GH, Bussink AP, Andrews L, Blommaart EF, Sugar A, Verhoeven AJ, Boot RG, Aerts JM (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17:1505-1512 (Pubitemid 41631326)
145. van Es HH, Renkema H, Aerts H, Schurr E (1994) Enhanced lysosomal acidification leads to increased chloroquine accumulation in CHO cells expressing the pfmdr1 gene. Mol Biochem Parasitol 68:209-219
146. Van Weely S, Van Leeuwen MB, Jansen ID, De Bruijn MA, Brouwer- Kelder EM, Schram AW, Sa Miranda MC, Barranger JA, Petersen EM, Goldblatt J et al (1991) Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta 1096:301-311
147. van Weely S, Brandsma M, Strijland A, Tager JM, Aerts JM (1993a) Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim Biophys Acta 1181:55-62 (Pubitemid 23087522)
148. van Weely S, van den Berg M, Barranger JA, Sa Miranda MC, Tager JM, Aerts JM (1993b) Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. J Clin Invest 91:1167-1175
149. Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, Helmond MT, Scheij S, Aerts JM (2006a) Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 89:239-244 (Pubitemid 44442987)
150. Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE (2006b) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29:106-111
151. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE (2007a) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2:e598
152. Vedder AC, Gerdes VE, Poorthuis BJ, Helmond M, Trip MD, Aerts JM, Hollak CE (2007b) Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males. J Inherit Metab Dis 30:988
153. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007c) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68-78 (Pubitemid 46140228)
154. Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, Ten Berge IJ, Groener JE, Aerts JM, Wanner C, Hollak CE (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94:319-325
155. Vedder AC, Biró E, Aerts JM, Nieuwland R, Sturk G, Hollak CE (2009) Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dial Transplant 24:3074-3081
156. Vissers JP, Langridge JI, Aerts JM (2007) Analysis and Quantification of Diagnostic Serum Markers and Protein Signatures for Gaucher Disease. Mol Cell Proteomics 6:755-766 (Pubitemid 46831929)
157. vom Dahl S, Harzer K, Rolfs A, Albrecht B, Niederau C, Vogt C, van Weely S, Aerts J, Müller G, Häussinger D (1999) Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J Hepatol 31:741-746
158. Wennekes T, van den Berg RJ, Boot RG, van der Marel GA, Overkleeft HS, Aerts JM (2009) Glycosphingolipids-nature, function, and pharmacological modulation. Angew Chem Int Ed Engl 48:8848-8869
159. Whitfield PD, Calvin J, Hogg S, O'Driscoll E, Halsall D, Burling K, Maguire G, Wright N, Cox TM, Meikle PJ, Deegan PB (2005) Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J Inherit Metab Dis 28(1):21-33 (Pubitemid 40253981)
160. Witte MD, Kallemeijn WW, Aten J, Li KY, Strijland A, Donker-Koopman WE, van den Nieuwendijk AM, Bleijlevens B, Kramer G, Florea BI, Hooibrink B, Hollak CE, Ottenhoff R, Boot RG, van der Marel GA, Overkleeft HS, Aerts JM (2010) Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol 6(12):907-913
161. Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, Hammer RE, Hamra FK, Matern S, Russell DW (2006) Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest 116:2985-2994 (Pubitemid 44684483)
162. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, Winchester B (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 94(447):51-54